Option Care Selected as Provider of RELiZORB for Patients Requiring Nutritional Support
By: Option Care
December 8, 2015
Option Care 被选定为史无前例改善消化的产品供应商，该产品面向患复杂病症需要营养支持的患者
DEERFIELD, Ill. — Option Care Enterprises, Inc., a leading national provider of home and alternate treatment site infusion services, has been selected as the contracted provider of RELiZORB™ (immobilized lipase), which helps patients with complex medical conditions digest and absorb the “essential fats “ they receive through enteral nutrition (tube feeding). Relizorb is manufactured by Alcresta Pharmaceuticals, Inc.
What is RELiZORB™
Recently approved as a de novo device by the U.S. Food and Drug Administration, Relizorb is a first-of-its-kind digestive enzyme cartridge designed to mimic the normal pancreatic function by breaking down fats in enteral tube feeding formula. By breaking down these fats prior to ingestion, Relizorb allows for the delivery of increased absorbable calories from fatty acids and monoglycerides to adults who are partially or completely unable to breakdown and absorb fats. Relizorb has been shown to break down 90 percent of fats in most enteral feeding tube formulas, including the most difficult to breakdown long-chain polyunsaturated fatty acids, which are critical for growth and development.
“We’re so pleased to be chosen to provide such an innovative product, which we believe can improve the quality of life for patients in need of nutrition therapy, “ said Kimberly Petruccelli, PharmD, MBA, clinical program manager of specialty infusion programs for Option Care. “Our registered dietitians have extensive experience and expertise caring for patients in need of complex therapies, including enteral nutrition, and can ensure they receive the highest level of care. “
Option Care & RELiZORB™
Option Care 凭借其通过营养支持项目提供个性化治疗，遵循多学科患者护理团队方法，在每一个分支机构中都配备有一名注册营养师，而当选为 Relizorb 的提供者并为其用药提供支持。作为全美最大的家庭和备选医疗站点输液服务提供者之一，Option Care 有能力通过其遍及全美的 92 家输液药房提供安全有效的营养护理。
“Option Care will play a key role in bringing Relizorb to patients through its dietitian-led patient care teams, “ said John Tucker, chief executive officer of Alcresta. “The company is an ideal partner because of its proven track record of providing high-quality care and its national presence with patients, payers and providers. “
“Option Care is honored to have been selected by Alcresta as the Relizorb provider of choice, and we’re committed to making this product an accessible option for patients, providers and payers, “ said Matthew Deans, vice president of business development for Option Care. “We believe that in developing customized clinical management programs in partnership with biopharmaceutical manufacturers, we can increase patient access to novel therapies. It’s our priority that patients receive the full therapeutic benefit of the treatment, which can lead to increased satisfaction, improved outcomes and lower total cost of care. “
关于 Option Care
Option Care Enterprises, Inc., offers clinical care provided by specially trained infusion nurses, pharmacists and dietitians who treat patients with a wide range of acute, chronic and rare conditions. As one of the nation’s largest providers of home and alternate treatment site infusion services, Option Care has 92 infusion pharmacies and 110 alternate treatment sites across the country. Learn more at www.OptionCare.com.
# # #
媒体联系人信息
Option Care
Lauren Kotarski
312-558-1770
LKotarski@pcipr.com
You might also be interested in:
Option Care 被选定为专门为遗传因子 X 缺乏症提供治疗的第一家也是唯一一家服务机构
DEERFIELD, Ill. — Option Care Enterprises, Inc., an independent infusion services company, has been selected as a contracted provider of Coagadex ® (Coagulation Factor X Human), the first and only treatment approved by the U.S. Food and Drug Administration specifically for hereditary factor X deficiency, a rare and serious bleeding disorder. Coagadex is manufactured by […]
Option Care 家庭输液血友病患者使用较少的第八因子，研究表明既节省了成本又不影响疗效
ORLANDO, FL, July 26, 2016 — Hemophilia patients can be managed with less factor VIII without affecting outcomes and saving significant costs, suggests a study being presented at the World Federation of Hemophilia 2016 World Congress meeting today in Orlando. The Option Care study included 77 hemophilia A patients receiving home infusion of factor VIII. […]